PL1773811T3 - Krystaliczny zmienny hydrat soli hemibursztynianowej (s)-6-(4-(2-((3(9h-karbazol-4-iloksy)-2-hydroksypropylo)amino)-2-metylopropylo)fenoksy)-3-pirydynokarboksy amidu - Google Patents

Krystaliczny zmienny hydrat soli hemibursztynianowej (s)-6-(4-(2-((3(9h-karbazol-4-iloksy)-2-hydroksypropylo)amino)-2-metylopropylo)fenoksy)-3-pirydynokarboksy amidu

Info

Publication number
PL1773811T3
PL1773811T3 PL05772857T PL05772857T PL1773811T3 PL 1773811 T3 PL1773811 T3 PL 1773811T3 PL 05772857 T PL05772857 T PL 05772857T PL 05772857 T PL05772857 T PL 05772857T PL 1773811 T3 PL1773811 T3 PL 1773811T3
Authority
PL
Poland
Prior art keywords
carbazol
yloxy
methylpropyl
phenoxy
hydroxypropyl
Prior art date
Application number
PL05772857T
Other languages
English (en)
Inventor
Julie Kay Bush
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of PL1773811T3 publication Critical patent/PL1773811T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PL05772857T 2004-07-22 2005-07-14 Krystaliczny zmienny hydrat soli hemibursztynianowej (s)-6-(4-(2-((3(9h-karbazol-4-iloksy)-2-hydroksypropylo)amino)-2-metylopropylo)fenoksy)-3-pirydynokarboksy amidu PL1773811T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US59025104P 2004-07-22 2004-07-22
PCT/US2005/024886 WO2006019835A1 (en) 2004-07-22 2005-07-14 A crystalline variable hydrate of (s)-6-(4-(2-((3-(9h-carbazol-4-yloxy)-2-hydroxypropyl)amino)-2-methylpropyl)phenoxy)-3-pyridinicarbox amide hemisuccinate salt
EP05772857A EP1773811B1 (en) 2004-07-22 2005-07-14 A crystalline variable hydrate of (s)-6-(4-(2-((3-(9h-carbazol-4-yloxy)-2-hydroxypropyl)amino)-2-methylpropyl)phenoxy)-3-pyridinecarbox amide hemisuccinate salt

Publications (1)

Publication Number Publication Date
PL1773811T3 true PL1773811T3 (pl) 2011-02-28

Family

ID=35106749

Family Applications (1)

Application Number Title Priority Date Filing Date
PL05772857T PL1773811T3 (pl) 2004-07-22 2005-07-14 Krystaliczny zmienny hydrat soli hemibursztynianowej (s)-6-(4-(2-((3(9h-karbazol-4-iloksy)-2-hydroksypropylo)amino)-2-metylopropylo)fenoksy)-3-pirydynokarboksy amidu

Country Status (17)

Country Link
US (1) US7834187B2 (pl)
EP (2) EP1773811B1 (pl)
JP (1) JP4922163B2 (pl)
CN (1) CN1989129B (pl)
AT (1) ATE480534T1 (pl)
AU (1) AU2005275185B2 (pl)
BR (1) BRPI0513569A2 (pl)
CA (1) CA2572631C (pl)
CY (1) CY1110806T1 (pl)
DE (1) DE602005023474D1 (pl)
DK (1) DK1773811T3 (pl)
ES (1) ES2349798T3 (pl)
MX (1) MX2007000892A (pl)
PL (1) PL1773811T3 (pl)
PT (1) PT1773811E (pl)
SI (1) SI1773811T1 (pl)
WO (1) WO2006019835A1 (pl)

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4235919A (en) * 1977-07-21 1980-11-25 Sandoz Ltd. 1-(Indol-4-yloxy)-3-(2-substituted amino)-2-propanols and pharmaceutical use thereof
EP0827746B1 (en) * 1996-09-05 2002-04-03 Eli Lilly And Company Carbazole analogues as selective beta3 adrenergic agonists
EP1204656A2 (en) * 1999-07-29 2002-05-15 Eli Lilly And Company A crystalline form of 6-hydroxy-3-(4-[2-(piperidin-1-yl) ethoxy] phenoxy)-2-(4-methoxyphenyl) benzo[b]thiophene hydrochloride
ES2208384T3 (es) * 1999-07-29 2004-06-16 Eli Lilly And Company Forma cristalina de clorhidrato de 6 hidroxi-3-(4-(2-(piperidin-1-il)-etoxi)-fenoxi)2--(4-metoxifenil)-benzo(b)tiofeno.
CZ20031098A3 (cs) * 2000-10-20 2003-08-13 Eli Lilly And Company Nová krystalická forma 6-hydroxy-3-(4-[2-(piperidin-1-yl)ethoxy]fenoxy)-2-(4-methoxyfenyl)benzo[b]thiofen hydrochloridu
US6627646B2 (en) * 2001-07-17 2003-09-30 Sepracor Inc. Norastemizole polymorphs
SI1419151T1 (sl) * 2001-08-15 2014-04-30 Pharmacia & Upjohn Company Llc Kristali, ki vključujejo sol jabolčne kisline N-(2-(dietilamino)etil)-5-((5-fluoro-1,2-dihidro-2-okso-3H-indol-3- iliden)metil)-2,4-dimetil-1H-pirol-3-karboksamida, postopki za njihovo pripravo in sestavki le-teh

Also Published As

Publication number Publication date
ATE480534T1 (de) 2010-09-15
DK1773811T3 (da) 2010-12-13
JP2008507519A (ja) 2008-03-13
EP1773811A1 (en) 2007-04-18
CY1110806T1 (el) 2015-06-10
AU2005275185A1 (en) 2006-02-23
ES2349798T3 (es) 2011-01-11
CA2572631C (en) 2012-05-15
CN1989129A (zh) 2007-06-27
MX2007000892A (es) 2007-05-23
DE602005023474D1 (en) 2010-10-21
US20080058385A1 (en) 2008-03-06
EP1773811B1 (en) 2010-09-08
AU2005275185B2 (en) 2011-06-23
PT1773811E (pt) 2010-10-19
CN1989129B (zh) 2010-11-10
EP2233482A1 (en) 2010-09-29
JP4922163B2 (ja) 2012-04-25
SI1773811T1 (sl) 2011-01-31
CA2572631A1 (en) 2006-02-23
WO2006019835A1 (en) 2006-02-23
BRPI0513569A2 (pt) 2012-10-09
US7834187B2 (en) 2010-11-16

Similar Documents

Publication Publication Date Title
UA85686C2 (ru) Метансульфонат этилового эфира 3-[(2-{[4-(гексилоксикарбониламиноиминометил)фениламино]метил}- 1-метил-1h-бензимидазол-5-карбонил)пиридин-2-иламино]пропионовой кислоты и его применение как лекарственного средства, способ его получения
NZ594385A (en) Aminopyrimidines useful as kinase inhibitors
BRPI0418149A (pt) derivados heterocìclicos como agonistas do receptor de gprc
MY169840A (en) Isoxazolines for controlling invertebrate pests
NZ700778A (en) Crystalline forms of 3-(2,6-dichloro-3,5-dimethoxy-phenyl)-1-{ 6-[4-(4-ethyl-piperazin-1-yl)-phenylamino]-pyrimidin-4-yl} -1-methyl-urea and salts thereof.
IL162979A (en) 4-[(4-methyl-4-oxido-1-piperazinyl)-methyl]-n-{4-methyl-3[[4-(3-pyridinyl)-2-pyrimidinyl]-amino]-phenyl}-benzamide, pharmaceutical compositions comprising it and use thereof for the preparation of medicaments for the treatment of a proliferative disorder
PE20060873A1 (es) Compuestos de quinolina heteroaromaticos
PE20060243A1 (es) Derivados de 4-amino insustituido-5-(4-urea-fenil)-pirrolotriazina
NO2010020I1 (no) 5-{{4-[(2,3-dimetyl-2H-indazot-6-yl)(metyl)amino]pyrimidin-2-yl}amino)-2-metylbenzensulfonamid Pazopanib.
PL350185A1 (en) Process for the production of tert-butyl (e)-(6-[2- [4-(4-fluorophenyl) -6-isopropyl-2-[ methyl (methylsulfonyl) amino] pyrimidin-5-yl] vinyl](4r, 6s)-2,2-dimethyl [1,3]dioxan-4-yl) acetate
WO2006067103A3 (en) Process for the preparation of a 2-pyridylethylcarboxamide derivative
NZ588652A (en) Carboxamide compounds for the treatment of metabolic disorders
DK1585743T3 (da) 2-(H-indazol-6-ylamino)-benzamid forbindelser som protein kinase inhibitorer, nyttige til behandling opthalmiske sygdomme
EP2578574A4 (en) OPTICALLY ACTIVE DIBENZYLAMINE DERIVATIVE AND METHOD OF MANUFACTURING THEREOF
EP1533304A4 (en) AMIDE DERIVATIVE
NO20055256D0 (no) 4-(4-heterosyklylalkoksy)fenyl)-1-(heterosyklyl-karbonyl)piperidinderivater og beslektede forbindelser som histamin H3-antagonister for behandling av neurologiske sykdommer som Alzheimers
NO20075086L (no) Behandling av Parkinsons sykdom, obstruktiv sovn apne, demens med Lewy legemer, vaskulaer demens med ikke-imidazol alkylamin histamin H3-reseptor ligander
ATE435217T1 (de) 4-(3- (2-phenyl-oxazol-4-ylmethoxy)- cyclohexyloxy)-butansäure derivate und verwandte verbindungen als ppar modulatoren zur behandlung von typ 2 diabetes und atherosklerose
UA92354C2 (en) Amino acid salts of rosiglitazone
SI1773811T1 (sl) Kristalinski variabilni hidrati (S)-6-(4-(2((3-(9h-karbazol-4-iloksi)-2-hidroksipropil)amino)-2-metil- propil)fenoksi)-3-piridinkarboksamid hemisukcinatne soli
DK1565440T3 (da) Ny fremgangsmåde til fremstilling af 2-aminomethylpyridinderivater
BR0201569A (pt) 4-(2-piridil) piperizinas possuindo uma atividade agonista do receptor 5ht7
ATE297902T1 (de) Sulfonyl-pyridazinon-derivate zur verwendung als aldose-reduktase-inhibitoren
NZ598777A (en) Methylpyrrolopyrimidinecarboxamides
AU2003303098A8 (en) Process for the preparation of 2-aminomethylpyridine derivative